Barclays Increases Amedisys (AMED) Price Target to $120.00
Amedisys (NASDAQ:AMED) had its target price boosted by Barclays from $115.00 to $120.00 in a research note published on Thursday morning. They currently have an equal weight rating on the health services provider’s stock.
A number of other equities analysts have also recently issued reports on AMED. Zacks Investment Research upgraded shares of Amedisys from a hold rating to a buy rating and set a $142.00 price objective on the stock in a research report on Tuesday, January 29th. Craig Hallum decreased their price objective on shares of Amedisys from $132.00 to $124.00 and set a hold rating on the stock in a research report on Friday, March 1st. They noted that the move was a valuation call. ValuEngine cut shares of Amedisys from a strong-buy rating to a buy rating in a research report on Wednesday, February 27th. BidaskClub cut shares of Amedisys from a strong-buy rating to a buy rating in a research report on Thursday, February 28th. Finally, SunTrust Banks boosted their price objective on shares of Amedisys to $145.00 and gave the company a buy rating in a research report on Friday, March 1st. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $124.72.
AMED stock opened at $122.60 on Thursday. Amedisys has a 12-month low of $59.08 and a 12-month high of $140.91. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of 33.77, a PEG ratio of 1.54 and a beta of 1.37. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.01 and a current ratio of 1.01.
In other news, insider David B. Pearce sold 4,370 shares of Amedisys stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $120.01, for a total transaction of $524,443.70. Following the sale, the insider now owns 13,129 shares of the company’s stock, valued at approximately $1,575,611.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey A. Rideout sold 1,411 shares of Amedisys stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $121.58, for a total transaction of $171,549.38. Following the sale, the director now directly owns 4,557 shares in the company, valued at approximately $554,040.06. The disclosure for this sale can be found here. Insiders have sold a total of 8,281 shares of company stock worth $993,393 in the last ninety days. Insiders own 2.60% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in AMED. First Hawaiian Bank boosted its stake in shares of Amedisys by 45.6% during the 4th quarter. First Hawaiian Bank now owns 415 shares of the health services provider’s stock valued at $49,000 after purchasing an additional 130 shares in the last quarter. Financial Gravity Companies Inc. bought a new stake in Amedisys during the fourth quarter worth about $50,000. Meeder Asset Management Inc. boosted its stake in Amedisys by 107.4% during the fourth quarter. Meeder Asset Management Inc. now owns 477 shares of the health services provider’s stock worth $56,000 after acquiring an additional 247 shares in the last quarter. Captrust Financial Advisors boosted its stake in Amedisys by 161.8% during the fourth quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock worth $70,000 after acquiring an additional 369 shares in the last quarter. Finally, Group One Trading L.P. bought a new stake in Amedisys during the fourth quarter worth about $90,000. 89.99% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
See Also: Leveraged Buyout (LBO)
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.